Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) have earned an average rating of "Moderate Buy" from the six analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $57.22.

Several research analysts have commented on ZLAB shares. Leerink Partners set a $75.00 target price on shares of Zai Lab and gave the stock an "outperform" rating in a research report on Monday, June 30th. Wall Street Zen cut shares of Zai Lab from a "buy" rating to a "hold" rating in a research report on Friday, June 27th. Finally, Citigroup restated a "buy" rating and issued a $69.00 target price (up previously from $66.00) on shares of Zai Lab in a research report on Monday, August 11th.

Insider Activity at Zai Lab

In other news, CFO Yajing Chen sold 9,618 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $30.00, for a total value of $288,540.00. Following the completion of the transaction, the chief financial officer directly owned 17,429 shares in the company, valued at $522,870. This trade represents a 35.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director William Lis sold 13,814 shares of the stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $35.67, for a total transaction of $492,745.38. Following the completion of the transaction, the director owned 35,106 shares of the company's stock, valued at $1,252,231.02. This trade represents a 28.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 218,687 shares of company stock valued at $7,637,554. Insiders own 4.96% of the company's stock.

Institutional Trading of Zai Lab

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Principal Financial Group Inc. lifted its stake in Zai Lab by 63.6% during the first quarter. Principal Financial Group Inc. now owns 2,884,810 shares of the company's stock valued at $104,257,000 after purchasing an additional 1,121,856 shares during the last quarter. RTW Investments LP acquired a new stake in Zai Lab during the fourth quarter valued at approximately $65,714,000. Price T Rowe Associates Inc. MD lifted its stake in Zai Lab by 30.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,354,025 shares of the company's stock valued at $61,653,000 after purchasing an additional 548,378 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Zai Lab by 46,222.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,132,201 shares of the company's stock valued at $77,058,000 after purchasing an additional 2,127,598 shares during the last quarter. Finally, Allianz Asset Management GmbH lifted its stake in Zai Lab by 25.1% during the first quarter. Allianz Asset Management GmbH now owns 1,884,411 shares of the company's stock valued at $68,103,000 after purchasing an additional 378,545 shares during the last quarter. 41.65% of the stock is owned by institutional investors and hedge funds.

Zai Lab Stock Down 0.1%

ZLAB opened at $35.69 on Tuesday. The firm has a market cap of $3.96 billion, a price-to-earnings ratio of -17.50 and a beta of 1.03. Zai Lab has a fifty-two week low of $16.56 and a fifty-two week high of $44.34. The company's 50-day moving average price is $36.63 and its 200 day moving average price is $33.64.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.37) EPS for the quarter, hitting the consensus estimate of ($0.37). Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. The firm had revenue of $109.98 million during the quarter, compared to analysts' expectations of $125.66 million. Research analysts anticipate that Zai Lab will post -2.58 earnings per share for the current year.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.